-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $12

Benzinga·12/09/2025 15:32:42
語音播報
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $8 to $12.